Hamilton Lane Advisors’s Agios Pharmaceuticals AGIO Stock Holding History

Hamilton Lane Advisors’s Portfolio AGIO Stock Details AGIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-56,170	Closed	-$2.89M	–	51
2017 Q2	$2.89M	Buy	+56,170	New	+$2.87M	1.58%	17
2016 Q4	–	Sell	-19,280	Closed	-$1.02M	–	64
2016 Q3	$1.02M	Buy	+19,280	New	+$840K	0.51%	39
2015 Q2	–	Sell	-80,439	Closed	-$7.58M	–	61
2015 Q1	$7.58M	Buy	+80,439	New	+$9.01M	3.46%	8
2014 Q4	–	Sell	-27,544	Closed	-$1.69M	–	53
2014 Q3	$1.69M	Sell	27,544 -264,357	-91%	-$11.4M	0.55%	29
2014 Q2	$13.4M	Buy	+291,901	New	+$11.9M	4.11%	4

Other funds holding AGIO

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Hamilton Lane Advisors's AGIO Position: Q3 2017 in Review

Hamilton Lane Advisors sold out of Agios Pharmaceuticals (AGIO) in Q3 2017, closing a stake of 56,170 shares — an estimated $2.89M sold.

Hamilton Lane Advisors first reported a position in AGIO in Q2 2014 and held it in 5 quarters. The position peaked at $13.4M in Q2 2014. 171 funds tracked by Wall St. Rank hold AGIO as of Q3 2017.

Hamilton Lane Advisors reported no remaining Agios Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
Hamilton Lane Advisors sold 56,170 Agios Pharmaceuticals shares in Q3 2017, an estimated $2.89M.
Hamilton Lane Advisors first reported a position in Agios Pharmaceuticals in Q2 2014 and held it in 5 quarters.
Hamilton Lane Advisors's Agios Pharmaceuticals position peaked at $13.4M in Q2 2014.
171 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q3 2017.

Based on Hamilton Lane Advisors's 13F filing for Q3 2017, filed 16 Oct 2017.